1.International research progress of risk factors, diagnosis and management in early chronic obstructive pulmonary disease.
Huiru LI ; Linqiong ZHOU ; Chunlei DUAN ; Weihong HAN ; Minghang WANG ; Suyun LI
Chinese Critical Care Medicine 2023;35(12):1340-1344
Chronic obstructive pulmonary disease (COPD) has a high global morbidity and mortality and a severe disease burden, yet progress in treatment and prevention has been slow in recent decades. Early COPD has few symptoms and is severely underdiagnosed and undertreated; it is crucial to search for effective clues of early COPD and provide management interventions. By reviewing the definition, risk factors, diagnosis and management interventions, this study explores the disease evolution of early-stage COPD, which can help clinical practice to develop more effective preventive and therapeutic strategies for stopping or slowing down the natural progression of the disease, improving the long-term prognosis, and reducing the disease burden.
Humans
;
Pulmonary Disease, Chronic Obstructive/drug therapy*
;
Prognosis
;
Risk Factors
2.The research progress of high altitude environment-associated chronic obstructive pulmonary disease and therapeutic drugs.
Xiang-Hai ZENG ; Ge-Le SUONAN ; Qin HUANG ; Yu LI ; Xiao-Jing ZHANG ; Wen-Bin LI ; Rong WANG
Acta Physiologica Sinica 2023;75(5):691-702
The plateau environment is characterized by low oxygen, low air pressure, low temperature, and strong ultraviolet rays, etc. Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic lung disease. High altitude environment increases COPD prevalence, clinical manifestation and mortality. The therapeutic window of theophylline drugs for COPD is narrow, and the high altitude environment has an influence on the pharmacokinetics of the drugs. This review summarizes the differences in the prevalence, mortality, clinical manifestation and clinical symptoms of COPD in the plateau and plain, providing a basis for identifying the risk factors of COPD in the plateau areas. The effects of plateau hypoxic environment on the pharmacokinetics of COPD drugs were also discussed. It can provide a rationale for more effective prevention and treatment of COPD at high altitude.
Humans
;
Altitude
;
Pulmonary Disease, Chronic Obstructive/drug therapy*
;
Oxygen
;
Hypoxia
5.Analysis of acupoint selection of plaster therapy in treatment of stable chronic obstructive pulmonary disease based on data mining.
Qing CAO ; Qing MIAO ; Xing LIAO ; Chang-Zheng FAN ; Mao-Rong FAN ; Yi-Ling FAN ; Ma QIU-XIAO ; Ning WANG ; Ya-Ni HAO
China Journal of Chinese Materia Medica 2020;45(22):5356-5361
This article analyze acupoint selection and characteristics of plaster therapy for stable chronic obstructive pulmonary di-sease(COPD) by data mining. The CNKI, VIP, CBM, WanFang, PubMed, EMbase, Cochrane Library were retrieved for collecting clinical studies of plaster therapy for stable COPD. After literature screening, a total of 46 systematic reviews were included. Frequency statistics, cluster analysis, and Apriori correlation analysis were used to analyze the pattern and characteristics of plaster therapy for stable COPD. The result showed that the main acupoints for stable COPD were BL13, Dingchuan, CV22, BL23 and BL20. The acupoints used are mainly concentrated on the chest and back. The most frequently used meridian is the bladder meridian. Analysis of the acupoints yielded 27 correlation rules. And cluster analysis grouped the high frequency acupoints into 5 categories. The results of the study showed that the current choice of acupoints is rather concentrated. "Local acupuncture points" and "matching points with front and back" were the main acupoint selection rules. The choice of acupuncture points reflected the traditional Chinese medicine treatment principle of strengthening healthy Qi to eliminate pathogenic factor, treating both manifestation and root cause of disease, and preventing measure taken after the occurrence of disease.
Acupuncture Points
;
Acupuncture Therapy
;
Data Mining
;
Humans
;
Meridians
;
Pulmonary Disease, Chronic Obstructive/drug therapy*
7.Pharmacotherapy in Stable Chronic Obstructive Pulmonary Disease.
Journal of the Korean Medical Association 2006;49(4):333-341
The general approach to manage stable COPD is characterized by a stepwise increase in treatment, depending on the severity of the disease. None of the existing medications for COPD have been shown to modify the long-term decline in lung function that is the hallmark of the disease. Therefore, pharmacotherapy in COPD is used to decrease symptoms and /or complications. Bronchodilator medications are central to the symptomatic management of COPD. They are given on an as-needed basis or on a regular basis to prevent or reduce symptoms. The principal bronchodilator treatments are beta2-agonists, anticholinergics, theophylline, and a combination of these drugs. Regular treatment with long-acting bronchodilators is more effective and convenient than treatment with short-acting bronchodilators, but more expensive. The addition of regular treatment with inhaled steroids to bronchodilator treatment is appropriate for symptomatic COPD patients with an FEV1<50% predicted (Stage III: Severe COPD and Stage IV: Very Severe COPD) or repeated exacerbations (for example, more than 3 times during the last 3 years). Chronic treatment with systemic steroids should be avoided, if possible.
Bronchodilator Agents
;
Cholinergic Antagonists
;
Drug Therapy*
;
Humans
;
Lung
;
Pulmonary Disease, Chronic Obstructive*
;
Steroids
;
Theophylline
10.Network Meta-analysis of oral Chinese patent medicines in treatment of acute exacerbation of chronic obstructive pulmonary disease.
Meng-Yao DING ; Shu-Guang YANG ; Ning-Xia YU ; Yun-Zhe HONG ; Zi-Chun YE ; Xue-Qing YU
China Journal of Chinese Materia Medica 2023;48(12):3373-3385
This study aimed to evaluate the effectiveness and safety of eight oral Chinese patent medicines in the treatment of acute exacerbation of chronic obstructive pulmonary disease(AECOPD) by network Meta-analysis. Randomized controlled trial(RCT) on the treatment of AECOPD with eight oral Chinese patent medicines was retrieved from databases including CNKI, Wanfang, VIP, SinoMed, PubMed, Web of Science, EMbase, and Cochrane Library from database inception to August 6, 2022. The information was extracted from the included literature and the quality of the included studies was evaluated using the Cochrane risk of bias assessment tool. The data were analyzed using Stata SE 15.1 and ADDIS 1.16.8 software. Finally, 53 RCTs were included, with 5 289 patients involved, including 2 652 patients in the experimental group and 2 637 patients in the control group. Network Meta-analysis showed that Lianhua Qingwen Capsules+conventional western medicine were optimal in improving clinical effective rate, Shufeng Jiedu Capsules+conventional western medicine in improving FEV1/FVC, Qingqi Huatan Pills+conventional western medicine in improving FEV1%pred, Feilike Mixture(Capsules)+conventional western medicine in improving PaO_2, Lianhua Qingwen Capsules+conventional western medicine in reducing PaCO_2, and Qingqi Huatan Pills+conventional western medicine in reducing C-reactive protein(CRP). In terms of safety, most of them were gastrointestinal symptoms, and no serious adverse reactions were reported. When the clinical effective rate was taken as the comprehensive index of efficacy evaluation, Lianhua Qingwen Capsules+conventional western medicine were the most likely to be the best treatment for AECOPD. There are some limitations in the conclusion of this study. It only provides references for clinical medication.
Humans
;
Capsules
;
Network Meta-Analysis
;
Pulmonary Disease, Chronic Obstructive/drug therapy*
;
Medicine, Chinese Traditional